Coherus BioSciences logo
Coherus BioSciences CHRS
$ 1.61 -5.03%

Quarterly report 2025-Q3
added 11-06-2025

report update icon

Coherus BioSciences Market Cap 2011-2026 | CHRS

As of January 13, 2026 Coherus BioSciences has a market cap of $ 152 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Coherus BioSciences

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
209 M 524 M 933 M 1.34 B 1.28 B 850 M 583 M 1.17 B 492 M 184 M - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.34 B 184 M 757 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Adagene Adagene
ADAG
87.8 M $ 1.65 7.91 % $ 92.9 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
895 M $ 3.59 1.99 % $ 8.64 B australiaAustralia
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
6.25 B $ 66.05 2.3 % $ 8.83 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
424 M $ 1.52 -16.3 % $ 388 M britainBritain
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
Biogen Biogen
BIIB
19.3 B $ 184.48 -1.67 % $ 26.9 B usaUSA
AVROBIO AVROBIO
AVRO
56.3 M - 1083.1 % $ 745 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
BioNTech SE BioNTech SE
BNTX
62.9 B $ 102.17 2.32 % $ 27.2 B germanyGermany
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
AstraZeneca PLC AstraZeneca PLC
AZN
81.2 B $ 93.52 -1.2 % $ 96.9 B britainBritain
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
3.16 B $ 4.25 1.67 % $ 9.25 B israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
253 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
8.32 M - -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
117 M - -7.31 % $ 87 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
114 B $ 55.71 -0.28 % $ 113 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
7.37 B $ 207.49 2.22 % $ 5 B danmarkDanmark
Codiak BioSciences Codiak BioSciences
CDAK
240 M - -55.98 % $ 2.15 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
484 M - 1052.0 % $ 415 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
6.68 B - - $ 7.29 B usaUSA
Acasti Pharma Acasti Pharma
ACST
40.7 M - 4.01 % $ 150 M canadaCanada
Zai Lab Limited Zai Lab Limited
ZLAB
34.2 B $ 18.37 -0.97 % $ 18.2 B chinaChina
Catalyst Biosciences Catalyst Biosciences
CBIO
33.6 M $ 10.84 0.46 % $ 714 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
3.58 M - -16.75 % $ 25.8 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
1.31 M $ 25.59 -6.54 % $ 1.65 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
203 M $ 4.22 -4.2 % $ 116 M franceFrance
Clearside Biomedical Clearside Biomedical
CLSD
101 M - - $ 25.3 M usaUSA
Chimerix Chimerix
CMRX
104 M - - $ 756 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
2.05 B - -15.15 % $ 60.3 M britainBritain
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
6.55 B $ 37.35 -0.4 % $ 3.86 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
2.44 B $ 23.18 2.02 % $ 2.75 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
538 M - -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
12.1 M - 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
49 M - 4.14 % $ 49.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
2.7 B $ 55.11 3.49 % $ 4.45 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
3.34 B $ 55.17 2.47 % $ 4.65 B schweizSchweiz
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.72 M - - $ 7.46 M israelIsrael
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
973 M $ 3.53 -5.75 % $ 231 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
664 K - -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
1.31 B $ 29.43 6.09 % $ 1.43 B usaUSA